Posted by Michael Wonder on 01 Oct 2021
Xbrane Biopharma announces that partner Stada's marketing authorisation application for ranibizumab is submitted and validated by European Medicines Agency
30 September 2021 - Xbrane Biopharma today announces that a marketing authorisation Application for biosimilar ranibizumab submitted by its co-development and commercialisation partner, STADA Arzneimittel, has been validated by the EMA.
Submission took place on 9 September and validation by EMA was communicated today.
